Rosumore F 20 Tablet is a powerful lipid-lowering combination that unites Rosuvastatin 20 mg, a high-intensity statin, with Fenofibrate 160 mg, a fibrate-class medication. This fixed-dose combination is designed to address complex dyslipidemias, particularly in patients suffering from both elevated LDL-C (bad cholesterol) and high triglyceride levels. Rosuvastatin works by inhibiting the HMG-CoA reductase enzyme to reduce cholesterol production in the liver, while Fenofibrate activates PPAR-alpha receptors, leading to enhanced lipid metabolism and breakdown of triglyceride-rich particles. This dual mechanism offers comprehensive lipid control—reducing total cholesterol, LDL, triglycerides, and increasing HDL-C (good cholesterol). Rosumore F 20 is ideal for patients with mixed dyslipidemia, metabolic syndrome, or type 2 diabetes who are at high cardiovascular risk and require intensive lipid-lowering therapy. The 20 mg statin component ensures strong statin coverage, making this formulation suitable for patients who are not achieving lipid goals with monotherapy or lower combination strengths.
While generally well tolerated, Rosumore F 20 may cause side effects such as headache, muscle pain, back pain, abdominal discomfort, nausea, flatulence, and elevated liver enzymes. The risk of myopathy or rhabdomyolysis is higher with this high-dose statin-fibrate combination, especially in elderly patients or those with kidney disease. Other possible adverse effects include changes in renal function, pancreatitis, or gallstones. Patients should report any signs of unexplained muscle pain, dark-colored urine, or persistent fatigue. Periodic monitoring of liver function, renal function, and muscle enzymes (CPK) is recommended during long-term use.
Rosumore F 20 Tablet is indicated for the treatment of mixed dyslipidemia and severe hypertriglyceridemia in adults at high risk of cardiovascular events, especially those with coexisting conditions like diabetes mellitus, obesity, or coronary artery disease. It is also used as an adjunct to diet in patients who require intensive lipid profile improvement and are unresponsive to monotherapy.
Rosumore F 20 should be used only under the supervision of a qualified physician. It is contraindicated in patients with active liver disease, severe renal dysfunction, gallbladder disease, or known hypersensitivity to statins or fibrates. This medication is not recommended during pregnancy or breastfeeding. Alcohol intake should be limited to reduce liver stress. Patients should continue to follow a lipid-lowering diet and lifestyle modification plan along with the medication. Regular follow-up and blood tests are essential to ensure safety and therapeutic efficacy.
Store Rosumore F 20 Tablet in a cool, dry place, away from moisture and direct sunlight, at a temperature not exceeding 30°C. Keep out of reach of children. Do not use the medicine past its expiry date.